BAY 80-6946 (Copanlisib)

Bezeichnung:BAY 80-6946 (Copanlisib)

CAS-Nr1032568-63-0

Englisch Name:BAY 80-6946 (Copanlisib)

CBNumberCB52616024

SummenformelC23H28N8O4

Molgewicht480.52

MOL-Datei1032568-63-0.mol

BAY 80-6946 (Copanlisib) physikalisch-chemischer Eigenschaften

Dichte	1.51
storage temp.	Store at -20°C
Löslichkeit	insoluble in DMSO; insoluble in H2O; insoluble in EtOH
Aggregatzustand	solid
pka	8.42±0.20(Predicted)
Farbe	Off-white to light brown

Gefahreninformationscode (GHS)

BAY 80-6946 (Copanlisib) Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden
BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models.
Definition
ChEBI: Copanlisib is an imidazoquinazoline that is 2,3-dihydroimidazo[1,2-c]quinazoline substituted by (2-aminopyrimidine-5-carbonyl)amino, methoxy, and 3-(morpholin-4-yl)propoxy groups at positions 5, 7 and 8, respectively. It is a intravenous pan-class I PI3K inhibitor used for the treatment of relapsed follicular lymphoma in patients who have received at least 2 prior systemic therapies. It has a role as an EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor, an antineoplastic agent and an apoptosis inducer. It is a member of morpholines, an aromatic ether, a diether, a tertiary amino compound, a secondary carboxamide, a pyrimidinecarboxamide, an aminopyrimidine and an imidazoquinazoline.
Trademarks
Aliqopa
Allgemeine Beschreibung
Class: lipid kinase; Treatment: FL (IV infusion); Other name: BAY 80-6946; Elimination half-life = 52 h (IV); Protein binding = 84.2%
Pharmakokinetik
Copanlisib has poor oral bioavailability due to low permeability and poor solubility, and therefore, it is not suitable for an oral medication. Consequently, it was developed as an IV drug. IV infusion of copanlisib resulted in rapid distribution throughout the body and a prolonged elimination half-life (52 h).
target
pan-PI3K
Stoffwechsel
Copanlisib was the predominant component in human plasma, accounting for 84% of total radioactivity AUC, and the morpholinone metabolite 6 was the only circulating metabolite (about 5%).

BAY 80-6946 (Copanlisib) Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Send Inquriy